Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Medical Research
Published in: European Journal of Medical Research 1/2015

Open Access 01-12-2015 | Research

Comparison of the safety and efficacy of biodegradable polymer drug-eluting stents versus durable polymer drug-eluting stents: a meta-analysis

Authors: Jianfeng Lv, Yazhou Wu, Xingmei Zhang, Tao Jing, Li Zhang, Shifei Tong, Zhiyuan Song, Mingli Wang, Gang Wang, Luxiang Chi

Published in: European Journal of Medical Research | Issue 1/2015

Login to get access

Abstract

Background

A meta-analysis was conducted to assess the safety and efficacy of biodegradable polymer drug-eluting stents (BP-DESs).

Methods

PubMed, Science Direct, China National Knowledge Infrastructure, and Chongqing VIP databases were searched for randomized controlled trials comparing the safety and efficacy of BP-DESs versus durable polymer drug-eluting stents (DP-DESs). Efficacy included the prevalence of target lesion revascularization (TLR), target vessel revascularization (TVR), and late lumen loss (LLL), and safety of these stents at the end of follow-up for the selected research studies were compared.

Results

A total of 16 qualified original studies that addressed a total of 22,211 patients were included in this meta-analysis. In regard to efficacy, no statistically significant difference in TLR (odds ratio (OR) = 0.94, P = 0.30) or TVR (OR 1.01, P = 0.86) was observed between patients treated with BP-DESs and those with DP-DESs. However, there were significant differences in in-stent LLL (weighted mean difference [WMD] = −0.07, P = 0.005) and in-segment LLL (WMD = −0.03, P = 0.05) between patients treated with BP-DESs and with DP-DESs. In terms of safety, there was no significant difference in overall mortality (OR 0.97, P = 0.67), cardiac death (OR 0.99, P = 0.90), early stent thrombosis (ST) and late ST (OR 0.94, P = 0.76; OR 0.96, P = 0.73), or myocardial infarction (MI) (OR 0.99, P = 0.88) between patients treated with BP-DESs and with DP-DESs. However, there was a statistically significant difference in very late ST (OR 0.69, P = 0.007) between these two groups. In addition, the general trend of the rates of TVR and TLR of BP-DESs groups was lower than DP-DESs groups after a 1-year follow-up.

Conclusion

BP-DESs are safe, efficient, and exhibit superior performance to DP-DESs with respect to reducing the occurrence of very late ST and LLL. The general trend of the rates of TVR and TLR of BP-DESs groups was lower than DP-DESs groups after a 1-year follow-up.
Literature
1.
Byrne RA, Sarafoff N, Kastrati A, Schomig A. Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment. Drug Saf. 2009;32:749–70.CrossRefPubMed
2.
3.
Byrne RA, Joner M, Kastrati A. Polymer coatings and delayed arterial healing following drug-eluting stent implantation. Minerva Cardioangiol. 2009;57:567–84.PubMed
4.
Wilson GJ, Nakazawa G, Schwartz RS, Huibregtse B, Poff B, Herbst TJ, et al. Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries. Circulation. 2009;120:141–9.CrossRefPubMed
5.
Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998–1008.CrossRefPubMed
6.
Finn AV, Nakazawa G, Kolodgie FD, Virmani R. Temporal course of neointimal formation after drug-eluting stent placement: is our understanding of restenosis changing? JACC Cardiovasc Interv. 2009;2:300–2.CrossRefPubMed
7.
Holmes Jr DR, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 2004;109:634–40.CrossRefPubMed
8.
Falluji NM, Moliterno DJ. Restenosis and in-stent restenosis. In: Norell MS, Perrins J, Meier B, Lincoff AM, editors. Essential interventional cardiology. Secondth ed. Philadelphia: Saunders Ltd; 2008. p. 151–61.CrossRef
9.
Niemela KO. Biodegradable coating for drug-eluting stents—more than a facelift? Eur Heart J. 2008;29:1930–1.CrossRefPubMed
10.
Kosonen P, Vikman S, Jensen LO, Lassen JF, Harnek J, Olivecrona GK, et al. Intravascular ultrasound assessed incomplete stent apposition and stent fracture in stent thrombosis after bare metal versus drug-eluting stent treatment the Nordic Intravascular Ultrasound Study (NIVUS). Int J Cardiol. 2013;168:1010–6.CrossRefPubMed
11.
Dangas GD, Claessen BE, Mehran R, Brener S, Brodie BR, Dudek D, et al. Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol. 2012;59:1752–9.CrossRefPubMed
12.
Naidu SS, Krucoff MW, Rutledge DR, Mao VW, Zhao W, Zheng Q, et al. Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study. JACC Cardiovasc Interv. 2012;5:626–35.CrossRefPubMed
13.
Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol. 2007;27:1500–10.CrossRefPubMed
14.
Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193–202.CrossRefPubMed
15.
Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet. 2008;372:1163–73.CrossRefPubMed
16.
Grube E, Schofer J, Hauptmann KE, Nickenig G, Curzen N, Allocco DJ, et al. A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9-month outcomes with the JACTAX HD stent. JACC Cardiovasc Interv. 2010;3:431–8.CrossRefPubMed
17.
Garg S, Wykrzykowska J, Serruys PW, de Vries T, Buszman P, Trznadel S, et al. The outcome of bifurcation lesion stenting using a biolimus-eluting stent with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer. EuroIntervention. 2011;6:928–35.CrossRefPubMed
18.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.​cochrane-handbook.​org.
19.
Chevalier B, Serruys PW, Silber S, Garcia E, Suryapranata H, Hauptmann K, et al. Randomised comparison of Nobori, biolimus A9-eluting coronary stent with a Taxus (R), paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial. EuroIntervention. 2007;2:426–34.PubMed
20.
Byrne RA, Kufner S, Tiroch K, Massberg S, Laugwitz KL, Birkmeier A, et al. Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. Heart. 2009;95:1489–94.CrossRefPubMed
21.
Chevalier B, Silber S, Park SJ, Garcia E, Schuler G, Suryapranata H, et al. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberte paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial—phase 2. Circ Cardiovasc Interv. 2009;2:188–95.CrossRefPubMed
22.
Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet. 2011;378:1940–8.
23.
Byrne RA, Kastrati A, Massberg S, Wieczorek A, Laugwitz KL, Hadamitzky M, et al. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. J Am Coll Cardiol. 2011;58:1325–31.
24.
Maamoun W. Safety and efficacy of biodegradable polymer-coated biolimus-eluting stents. Egypt Heart J. 2013;65:207–12.CrossRef
25.
Kadota K, Muramatsu T, Iwabuchi M, Saito S, Hayashi Y, Ikari Y, et al. Randomized comparison of the Nobori biolimus A9-eluting stent with the sirolimus-eluting stent in patients with stenosis in native coronary arteries. Catheter Cardiovasc Interv. 2012;80:789–96.CrossRefPubMed
26.
Xu B, Dou K, Yang Y, Lv S, Wang L, Wang H, et al. Nine-month angiographic and 2-year clinical follow-up of the NOYA biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the NOYA I trial. EuroIntervention. 2012;8:796–802.CrossRefPubMed
27.
Jianqiao T, Xiwei D, Taojuan Z. Clinical application and effect analysis of novel biodegradable coated stent in the treatment of Macau Chinese patients with coronary heart disease. Chin J Clinicians. 2012;6:1712–5.
28.
29.
Smits PC, Hofma S, Togni M, Vázquez N, Valdés M, Voudris V, et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet. 2013;381:651–60.
30.
Zhang Y, Shen J, Li Z, Zhu AD, Yuan YL, Yue RH, et al. Two-year clinical outcomes of different drug-eluting stents with different polymer coating strategies in coronary artery heart disease: a multi-centre, randomised, controlled clinical trial. Int J Cardiol. 2013;168:2642–52.
31.
Natsuaki M, Kozuma K, Morimoto T, Kadota K, Toshiya Muramatsu T, Nakagawa Y, et al. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. J Am Coll Cardiol. 2013;63:181–90.CrossRef
32.
33.
Han YL, Xu B, Jing QM, Lu SZ, Yang LX, Xu K, et al. A randomized comparison of novel biodegradable polymer- and durable polymer–coated cobalt-chromium sirolimus-eluting stents. JACC Cardiovasc Interv. 2014;7:1352–461.CrossRefPubMed
34.
Pilgrim T, Heg D, Roffi M, Tüller D, Muller O, Vuilliomenet A, et al. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularization (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. Lancet. 2014;384:2111–22.
35.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.CrossRefPubMed
36.
Mehilli J, Byrne RA, Wieczorek A, Iijima R, Schulz S, Bruskina O, et al. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J. 2008;29:1975–82.CrossRefPubMed
37.
Lupi A, Rognoni A, Secco GG, Lazzero M, Nardi F, Fattori R, et al. Biodegradable versus durable polymer drug eluting stents in coronary artery disease: insights from a meta-analysis of 5,834 patients. Eur J Prev Cardiol. 2014;21:411–24.
38.
Klauss V, Serruys PW, Pilgrim T, Buszman P, Linke A, Ischinger T, et al. 2-year clinical follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice. JACC Cardiovasc Interv. 2011;4:887–95.CrossRefPubMed
39.
Byrne RA, Kastrati A, Kufner S, Massberg S, Birkmeier KA, Laugwitz KL, et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J. 2009;30:2441–9.CrossRefPubMed
40.
Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–51.CrossRefPubMed
41.
Notaristefano S, Sbarzaglia P. Cavallini C [Late stent thrombosis after drug-eluting stent implantation: epidemiological, clinical and pathophysiological aspects]. G Ital Cardiol (Rome). 2008;9:674–83.
42.
D’Ascenzo F, Bollati M, Clementi F, Castagno D, Lagerqvist B, de la Torre Hernandez JM, et al. Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int J Cardiol. 2013;167:575–84.CrossRefPubMed
Metadata
Title
Comparison of the safety and efficacy of biodegradable polymer drug-eluting stents versus durable polymer drug-eluting stents: a meta-analysis
Authors
Jianfeng Lv
Yazhou Wu
Xingmei Zhang
Tao Jing
Li Zhang
Shifei Tong
Zhiyuan Song
Mingli Wang
Gang Wang
Luxiang Chi
Publication date
01-12-2015
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2015
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-015-0110-z

Other articles of this Issue 1/2015

European Journal of Medical Research 1/2015 Go to the issue

Case report

Male breast carcinoma: radiotherapy contributed to favorable local control in two cases and related literature review

Case report

Benign orbital angiomatous tumors with intracranial extension

Research

Plate osteosynthesis versus hemiarthroplasty in proximal humerus fractures – Does routine screening of systemic inflammatory biomarkers makes sense?

Research

Perceptions of normal and abnormal ejaculatory latency times: an observational study in Ghanaian males and females

Research

Pronator quadratus repair after volar plating of distal radius fractures or not? Results of a prospective randomized trial

Retraction Note

Retraction Note: Triptolide ameliorates lipopolysaccharide-induced acute lung injury in rats